Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Research
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, in Preclinical Leukemia Models at the European Hematology Association Congress
WATERTOWN, Mass., June 09, 2023 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degr…
Patient Education Webcasts
Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)
Research
Immune-Onc Therapeutics Announces IO-202 Granted Fast Track Designation by FDA for the Treatment of Relapsed or Refractory CMML
PALO ALTO, CA, June 7, 2023 – Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage oncology company dedicated to the discovery and …
Patient Education Webcasts
Cafecito con LLS: Hablemos de la salud mental
News
Subaru Partners with The Leukemia & Lymphoma Society for 8th Year to Share Warmth, Love and Relief with Patients Facing Cancer
Subaru of America, Inc. is renewing its partnership with The Leukemia & Lymphoma Society (LLS) during Subaru Loves to Care® month in June. Subaru will…
News
FDA Approves New Bispecific Antibody for Non-Hodgkin Lymphoma Subtype
Epcoritamab gives patients with diffuse large B-cell lymphoma another treatment option.
Research
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
Heidelberg, Germany, May 23, 2023 – Affimed N.V. announced today that the U.S. Food and Drug Administration (FDA) has cleared its IND application for …
Patient Education Webcasts
Spotlight on Chronic Lymphocytic Leukemia (CLL)
News
Cancer Drug Shortages Greatly Affect Patients with Blood Cancer, Families Across the US
Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, releases statement noting that the LLS continues to advocate for solutions to keep…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
